News

Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform

PHILADELPHIA--(BUSINESS WIRE)--CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its team with the addition of Nigel Lindner, PhD as Chief Innovation Officer. Dr. Lindner brings over three decades of experience in advancing innovation in diagnostics, previously as Global Head of R&D at Alere, CEO of Swiss Precision Diagnostics, and CIO at LumiraDx. “We are incredibly excited about the opportunity to work closely with Dr. Lindner to validate and.

03/17/2025

Why Is LumiraDx (LMDX) Stock Down 13% Today?

LumiraDx (NASDAQ: LMDX ) stock is taking a beating on Monday as investors prepare for the point-of-care diagnostics company's shares to be suspended tomorrow. LumiraDx notes that shares of LMDX are going to be suspended from the Nasdaq Exchange at the start of business on Tuesday.

01/08/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is LumiraDx Limited (LMDX) a buy, sell, or hold?

LumiraDx Limited (LMDX) can hold. Click on Rating Page for detail.

What is LumiraDx Limited's stock price?

The price of LumiraDx Limited (LMDX) is 0.016 and it was updated on 2025-05-09 01:17:35.

Is LumiraDx Limited (LMDX) overvalued or undervalued?

Currently LumiraDx Limited (LMDX) is in undervalued.

News

From:

To:

News
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. Fri, Jan. 05, 2024
Roche to buy part of LumiraDx diagnostics platform for $295 million Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million. Fri, Dec. 29, 2023
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. Fri, Dec. 29, 2023
Best Penny Stocks Today? 3 To Watch Under $4 Now Penny stocks can offer traders massive profits through their sheer price volatility. With prices below $5 per share, these tiny companies allow you to snap up many shares. Thu, Nov. 30, 2023
Penny Stocks To Buy? 4 Under $5 To Watch Right Now When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks. Fri, Nov. 17, 2023

Transcripts

Transcipts Data
LumiraDx Limited (LMDX) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Thu, Aug. 24, 2023
LumiraDx Limited (LMDX) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Tue, May. 16, 2023
LumiraDx Limited (LMDX) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Tue, Mar. 21, 2023
LumiraDx Limited (LMDX) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Sat, Nov. 12, 2022
LumiraDx Limited (LMDX) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Thu, Aug. 18, 2022
LumiraDx Limited (LMDX) on Q1 2022 Results - Earnings Call Transcript SA Transcripts Wed, May. 11, 2022

SEC Filings

SEC Filings
LumiraDx Limited (LMDX) - SC 13G/A SEC Filings 11/12/2024
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 10/04/2024
LumiraDx Limited (LMDX) - 25-NSE SEC Filings 03/21/2024
LumiraDx Limited (LMDX) - SC 13G/A SEC Filings 02/12/2024
LumiraDx Limited (LMDX) - SC 13G/A SEC Filings 02/09/2024
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 02/06/2024
LumiraDx Limited (LMDX) - SC 13D/A SEC Filings 12/29/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 12/29/2023
LumiraDx Limited (LMDX) - SC 13D/A SEC Filings 12/26/2023
LumiraDx Limited (LMDX) - SC 13D/A SEC Filings 12/20/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 12/11/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 11/21/2023
LumiraDx Limited (LMDX) - SC 13D/A SEC Filings 11/08/2023
LumiraDx Limited (LMDX) - SC 13D/A SEC Filings 11/07/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 11/07/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 11/06/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 11/01/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 10/31/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 10/27/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 10/23/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 10/11/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 10/03/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 09/26/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 09/18/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 08/29/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 08/24/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 07/21/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 07/17/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 06/30/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 06/07/2023
LumiraDx Limited (LMDX) - EFFECT SEC Filings 05/16/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 05/16/2023
LumiraDx Limited (LMDX) - F-3 SEC Filings 05/04/2023
LumiraDx Limited (LMDX) - S-8 SEC Filings 05/01/2023
LumiraDx Limited (LMDX) - 20-F SEC Filings 05/01/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 04/24/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 04/06/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 03/21/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 03/07/2023
LumiraDx Limited (LMDX) - SC 13D/A SEC Filings 02/23/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 02/22/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 02/17/2023
LumiraDx Limited (LMDX) - SC 13D SEC Filings 02/14/2023
LumiraDx Limited (LMDX) - SC 13G/A SEC Filings 02/13/2023
LumiraDx Limited (LMDX) - SC 13G/A SEC Filings 02/10/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 01/31/2023
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 12/19/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 12/16/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 11/15/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 11/09/2022
LumiraDx Limited (LMDX) - EFFECT SEC Filings 10/06/2022
LumiraDx Limited (LMDX) - EFFECT SEC Filings 10/06/2022
LumiraDx Limited (LMDX) - POS AM SEC Filings 10/04/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 09/29/2022
LumiraDx Limited (LMDX) - 424B3 SEC Filings 09/29/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 09/28/2022
LumiraDx Limited (LMDX) - 424B3 SEC Filings 09/28/2022
LumiraDx Limited (LMDX) - SC 13D SEC Filings 09/07/2022
LumiraDx Limited (LMDX) - SC 13D SEC Filings 09/06/2022
LumiraDx Limited (LMDX) - SC 13D SEC Filings 08/24/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 08/18/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 08/16/2022
LumiraDx Limited (LMDX) - 424B3 SEC Filings 08/16/2022
LumiraDx Limited (LMDX) - SC 13D SEC Filings 08/03/2022
LumiraDx Limited (LMDX) - 424B3 SEC Filings 07/29/2022
LumiraDx Limited (LMDX) - SC 13D/A SEC Filings 07/28/2022
LumiraDx Limited (LMDX) - EFFECT SEC Filings 07/21/2022
LumiraDx Limited (LMDX) - EFFECT SEC Filings 07/21/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 07/21/2022
LumiraDx Limited (LMDX) - 424B4 SEC Filings 07/21/2022
LumiraDx Limited (LMDX) - F-1 SEC Filings 07/19/2022
LumiraDx Limited (LMDX) - CORRESP SEC Filings 07/19/2022
LumiraDx Limited (LMDX) - SC 13G SEC Filings 07/15/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 07/01/2022
LumiraDx Limited (LMDX) - UPLOAD SEC Filings 06/24/2022
LumiraDx Limited (LMDX) - DRS SEC Filings 06/21/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 06/21/2022
LumiraDx Limited (LMDX) - EFFECT SEC Filings 06/07/2022
LumiraDx Limited (LMDX) - EFFECT SEC Filings 06/07/2022
LumiraDx Limited (LMDX) - 424B3 SEC Filings 06/07/2022
LumiraDx Limited (LMDX) - 424B3 SEC Filings 06/06/2022
LumiraDx Limited (LMDX) - CORRESP SEC Filings 06/02/2022
LumiraDx Limited (LMDX) - F-1/A SEC Filings 05/27/2022
LumiraDx Limited (LMDX) - CORRESP SEC Filings 05/27/2022
LumiraDx Limited (LMDX) - UPLOAD SEC Filings 05/19/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 05/13/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 05/12/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 05/11/2022
LumiraDx Limited (LMDX) - S-8 SEC Filings 05/02/2022
LumiraDx Limited (LMDX) - F-1 SEC Filings 05/02/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 04/28/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 04/27/2022
LumiraDx Limited (LMDX) - 20-F SEC Filings 04/13/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 03/10/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 03/09/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 03/03/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 03/01/2022
LumiraDx Limited (LMDX) - SC 13G SEC Filings 02/24/2022
LumiraDx Limited (LMDX) - SC 13D SEC Filings 02/24/2022
LumiraDx Limited (LMDX) - SC 13G SEC Filings 02/14/2022
LumiraDx Limited (LMDX) - SC 13G SEC Filings 02/09/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 01/18/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 01/11/2022
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 11/22/2021
LumiraDx Limited (LMDX) - 6-K - Current report SEC Filings 11/10/2021
LumiraDx Limited (LMDX) - S-8 SEC Filings 09/29/2021
LumiraDx Limited (LMDX) - CERT SEC Filings 09/29/2021
LumiraDx Limited (LMDX) - 20-F SEC Filings 09/29/2021
LumiraDx Limited (LMDX) - CERT SEC Filings 09/28/2021
LumiraDx Limited (LMDX) - 8-A12B SEC Filings 09/28/2021
LumiraDx Limited (LMDX) - POS EX SEC Filings 09/27/2021
LumiraDx Limited (LMDX) - 424B3 SEC Filings 09/10/2021
LumiraDx Limited (LMDX) - SEC STAFF LETTER SEC Filings 09/08/2021
LumiraDx Limited (LMDX) - EFFECT SEC Filings 09/07/2021
LumiraDx Limited (LMDX) - EFFECT SEC Filings 09/03/2021
LumiraDx Limited (LMDX) - 424B3 SEC Filings 09/03/2021
LumiraDx Limited (LMDX) - F-4/A SEC Filings 09/01/2021
LumiraDx Limited (LMDX) - CORRESP SEC Filings 09/01/2021
LumiraDx Limited (LMDX) - F-4/A SEC Filings 08/27/2021
LumiraDx Limited (LMDX) - CORRESP SEC Filings 08/27/2021
LumiraDx Limited (LMDX) - UPLOAD SEC Filings 08/24/2021
LumiraDx Limited (LMDX) - F-4/A SEC Filings 08/20/2021
LumiraDx Limited (LMDX) - CORRESP SEC Filings 08/20/2021
LumiraDx Limited (LMDX) - 425 SEC Filings 08/20/2021
LumiraDx Limited (LMDX) - UPLOAD SEC Filings 07/23/2021
LumiraDx Limited (LMDX) - 425 SEC Filings 07/19/2021
LumiraDx Limited (LMDX) - F-4 SEC Filings 07/07/2021
LumiraDx Limited (LMDX) - CORRESP SEC Filings 07/07/2021
LumiraDx Limited (LMDX) - UPLOAD SEC Filings 06/28/2021
LumiraDx Limited (LMDX) - SEC STAFF LETTER SEC Filings 06/24/2021
LumiraDx Limited (LMDX) - DRS/A SEC Filings 06/16/2021
LumiraDx Limited (LMDX) - DRSLTR SEC Filings 06/15/2021
LumiraDx Limited (LMDX) - UPLOAD SEC Filings 05/18/2021
LumiraDx Limited (LMDX) - DRS SEC Filings 04/20/2021
LumiraDx Limited (LMDX) - RW SEC Filings 04/07/2021
LumiraDx Limited (LMDX) - F-1 SEC Filings 01/15/2021
LumiraDx Limited (LMDX) - DRS/A SEC Filings 12/23/2020
LumiraDx Limited (LMDX) - D SEC Filings 12/15/2020
LumiraDx Limited (LMDX) - DRS/A SEC Filings 10/14/2020
LumiraDx Limited (LMDX) - DRS/A SEC Filings 09/10/2020
LumiraDx Limited (LMDX) - DRS SEC Filings 08/03/2020
LumiraDx Limited (LMDX) - D/A SEC Filings 05/28/2020
LumiraDx Limited (LMDX) - D/A SEC Filings 04/21/2020
LumiraDx Limited (LMDX) - D SEC Filings 04/17/2020
LumiraDx Limited (LMDX) - D SEC Filings 04/03/2020
LumiraDx Limited (LMDX) - D SEC Filings 02/26/2020
LumiraDx Limited (LMDX) - D SEC Filings 09/04/2019
LumiraDx Limited (LMDX) - D SEC Filings 01/17/2019
LumiraDx Limited (LMDX) - D SEC Filings 12/13/2016
LumiraDx Limited (LMDX) - D SEC Filings 10/17/2016
LumiraDx Limited (LMDX) - D SEC Filings 10/13/2016

Press Releases

StockPrice Release
Former alere and lumiradx r&d chief nigel lindner joins cleu diagnostics to launch revolutionary labsimple diagnostic platform 03/17/2025
Lumiradx announces its securities will be suspended from trading on nasdaq at the open of business on january 9th 01/05/2024
Lumiradx announces agreement to sell its cutting edge point of care technology platform to roche 12/29/2023
Lumiradx announces receipt of nasdaq delisting determination; plans to appeal 10/27/2023
Lumiradx reports second quarter 2023 results 08/24/2023
Lumiradx to announce second quarter financial results and host quarterly conference call on august 24 08/16/2023
Lumiradx's point of care diagnostics group continues commercial expansion announcing a distribution agreement with axonlab for its lumiradx platform and tests 07/31/2023
Lumiradx submits first 510(k) application to the fda for covid ultra test 06/30/2023
Lumiradx receives uk ctda approval for covid ultra and covid & rsv tests 06/20/2023
Lumiradx reports first quarter 2023 results 05/16/2023
Lumiradx receives nasdaq notification regarding minimum bid price deficiency 04/24/2023
Lumiradx announces strategic refocus and cost restructuring program 04/06/2023
Lumiradx reports fourth quarter and full year 2022 results 03/21/2023
Lumiradx to announce fourth quarter and full year 2022 financial results and host quarterly conference call on march 21 03/14/2023
Lumiradx to present at raymond james institutional investors conference 03/03/2023
Lumiradx regains compliance with nasdaq continued listing requirements 02/17/2023
Lumiradx announces commercial shipment of its point of care nt-probnp test in europe, supporting heart health checks in uk 01/31/2023
Lumiradx announces receipt of nasdaq notification letter regarding minimum bid price deficiency 01/31/2023
Lumiradx announces new investment for ongoing development of its point of care molecular tuberculosis test 12/14/2022
Point of care (poc) survey reveals majority of u.k. clinicians endorse climate benefits of poc through reduction of carbon emissions and anticipate future growth of poc testing to come from community settings 12/08/2022
Lumiradx continues commercial expansion of its rapid microfluidic immunoassay hba1c test 11/14/2022
Lumiradx continues commercial expansion of its rapid microfluidic immunoassay hba1c test 11/14/2022
Lumiradx reports third quarter 2022 results 11/09/2022
Lumiradx to announce third quarter financial results and host quarterly conference call on november 9 11/02/2022
Lumiradx named by frost & sullivan as the 2022 europe technology innovation leader in the microfluidics point of care diagnostics industry 10/12/2022
Lumiradx partners with british in vitro diagnostics association to report on the role of rapid diagnostics in tackling antimicrobial resistance 09/22/2022
Lumiradx reports second quarter 2022 results 08/18/2022
Lumiradx to announce second quarter financial results and host quarterly conference call on august 18 08/11/2022
Lumiradx announces pricing of public offering of common shares and concurrent private placement 07/21/2022
Lumiradx announces proposed public offering of common shares 07/19/2022
Lumiradx achieves ce mark for covid-19 antigen test on amira, its new low-cost testing system 06/09/2022
Lumiradx receives ce mark for two multiplex tests: lumiradx dual-target sars-cov-2 star complete and lumiradx sars-cov-2 & flu a/b rna star complete 06/08/2022
Lumiradx hba1c test achieves ce mark, addresses growing global need for diabetes screening and monitoring with its next-generation point of care diagnostic platform 05/26/2022
Lumiradx receives who emergency use listing for sars-cov-2 ag test 05/20/2022
Lumiradx five-minute sars-cov-2 ag ultra test achieves ce marking 05/19/2022
Lumiradx to announce first quarter financial results and host quarterly conference call on may 11 04/29/2022
Lumiradx reports fourth quarter and full year 2021 results 03/10/2022
Lumiradx to announce fourth quarter and full year 2021 financial results and host quarterly conference call on march 10 03/03/2022
Lumiradx announces pricing of $56.5 million convertible notes offering 03/01/2022
Lumiradx lab analysis confirms its covid-19 antigen test detects the omicron variant 01/14/2022
Lumiradx has commenced shipments in europe for its covid-19 & flu a/b microfluidic antigen test 01/11/2022
Lumiradx crp test achieves ce marking 01/11/2022
Lumiradx covid-19 & flu a/b rapid antigen test achieves ce marking 12/23/2021
Lumiradx fast lab solutions partners with audere for at-home self- collection solution for use with sars-cov-2 rna star complete 12/15/2021
Audere receives fda emergency use authorization for healthpulse@home covid-19 specimen collection test kit 12/07/2021
Lumiradx reports third quarter 2021 financial results 11/10/2021
Lumiradx to announce third quarter 2021 financial results and host quarterly conference call on november 10 11/02/2021
Lumiradx receives approval for its covid-19 antigen test for use in india 10/20/2021

More Headlines

News
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimum Bid Price Requirement. The Notice states that because the Company has not regained compliance with the Minimum Bid Price Requirement, its securities are now subject to delisting from The Nasdaq Global Market. 10/27/2023
Why Is LumiraDx (LMDX) Stock Down 35% Today? LumiraDx (NASDAQ: LMDX ) stock is falling on Tuesday as the point-of-care diagnostics company's shares retreat from a rally on Monday. Investors will note that LMDX stock underwent a 217% rally on Monday. 10/24/2023
Why Is LumiraDx (LMDX) Stock Up 323% Today? LumiraDx (NASDAQ: LMDX ) stock is taking off on Monday with a new partnership with AstraZeneca (NASDAQ: AZN ) behind its rally. This collaboration has LumiraDx working together with AstraZeneca and Everton in the Community to set up the first community-based heart and lung screening hub in England. 10/23/2023
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO) The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 10/20/2023
LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner LumiraDx Limited (LMDX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. 09/27/2023
What Makes LumiraDx Limited (LMDX) a New Buy Stock LumiraDx Limited (LMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 09/21/2023
LumiraDx Limited (LMDX) Q2 2023 Earnings Call Transcript LumiraDx Limited (NASDAQ:LMDX ) Q2 2023 Earnings Call Transcript August 24, 2023 8:30 AM ET Company Participants Melissa Garcia - Vice President Corporate Counsel Ron Zwanziger - Chairman & Chief Executive Officer Dorian LeBlanc - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Jeffrey Cohen - Ladenburg Thalmann Andrew Cooper - Raymond James Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the LumiraDx Second Quarter 2023 Earnings Conference Call. 08/24/2023
LumiraDx Limited (LMDX) Reports Q2 Loss, Misses Revenue Estimates LumiraDx Limited (LMDX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.58 per share a year ago. 08/24/2023
LumiraDx Reports Second Quarter 2023 Results LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. 08/24/2023
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24 LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights. 08/16/2023
LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany 07/31/2023
Why Is LumiraDx (LMDX) Stock Up 30% Today? LumiraDx (NASDAQ: LMDX ) stock is heading higher on Wednesday morning after the company received approval for its Covid and RSV tests. The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) gave its approval to the company's test through its Coronavirus Test Device Approvals (CTDA) process. 06/21/2023
Best Penny Stocks to Buy Under $5? 4 To Watch Now Penny stocks are shares of companies that trade for less than $5. That's the standard definition of the term, but most traders who're familiar with the idea generally focus on cheaper stocks. 06/20/2023
LumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue Estimates LumiraDx Limited (LMDX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago. 05/16/2023
LumiraDx Limited (LMDX) Reports Q4 Loss, Tops Revenue Estimates LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -68.42% and 7.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? 03/21/2023
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21 LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21st, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights. 03/14/2023
LumiraDx to Present at Raymond James Institutional Investors Conference LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7th, 2023 at 4:35pm ET. Webcast link below. 03/03/2023
LumiraDx Limited (LMDX) Q3 2022 Earnings Call Transcript LumiraDx Limited (NASDAQ:LMDX ) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Tallman Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Thank you for joining LumiraDx Third Quarter 2022 Earnings Conference Call. 11/12/2022
LumiraDx Limited (LMDX) Reports Q3 Loss, Tops Revenue Estimates LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -56.67% and 46.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? 11/09/2022
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9 LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday, November 9th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights. 11/02/2022
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” 09/22/2022
LumiraDx Limited's (LMDX) CEO Ron Zwanziger on Q2 2022 Results - Earnings Call Transcript LumiraDx Limited (NASDAQ:LMDX ) Q2 2022 Earnings Conference Call August 18, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Pooja Pathak - Chief Product Officer Conference Call Participants Vijay Kumar - Evercore ISI Jeffrey Cohen - Ladenburg Mark Massaro - BTIG Operator Good day. And welcome to the LumiraDx Second Quarter 2022 Earnings Call. 08/18/2022
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18 LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights. 08/11/2022
Why LumiraDx Stock Is Crashing Today The company announced the share price of its public stock offering. 07/21/2022
Why LumiraDx Shares Are Rising Today LumiraDx Ltd (NASDAQ: LMDX) shares are trading higher by 10.31% at $4.28 after the company announced it achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete. LumiraDx says the SARS-. 06/08/2022
LumiraDx's (LMDX) CEO Ron Zwanziger On Q1 2022 Results - Earnings Call Transcript LumiraDx Ltd (NASDAQ:LMDX ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Colleen McMillen – Vice President-Communications Ron Zwanziger – Chairman and Chief Executive Officer Dorian LeBlanc – Chief Financial Officer Pooja Pathak – Chief Product Officer Conference Call Participants Vijay Kumar – Evercore ISI Jeffrey Cohen – Ladenburg Thalmann Andrew Cooper – Raymond James Operator Hello, and welcome to LumiraDx First Quarter 2022 Earnings Call. All participants will be in the listen-only mode. 05/11/2022
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11 LONDON , April 29, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Wednesday, May 11, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 4:30 PM Eastern Time to review the financial results and business highlights. 04/29/2022
Good Stocks To Buy Right Now? 4 Health Care Stocks For Your List Could health care stocks be the top picks in the stock market this week? 03/15/2022
LumiraDx Limited (LMDX) CEO Ron Zwanziger On Q4 2021 Results - Earnings Call Transcript LumiraDx Limited (LMDX) CEO Ron Zwanziger On Q4 2021 Results - Earnings Call Transcript 03/10/2022
LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10 LONDON, March 3, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8 AM Eastern Time to review the financial results and business highlights. 03/03/2022
Wall Street Analysts Believe LumiraDx Limited (LMDX) Could Rally 54%: Here's is How to Trade The mean of analysts' price targets for LumiraDx Limited (LMDX) points to a 53.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. 01/25/2022
LumiraDx Limited's (LMDX) CEO Ron Zwanziger On Q3 2021 Results - Earnings Call Transcript LumiraDx Limited's (LMDX) CEO Ron Zwanziger On Q3 2021 Results - Earnings Call Transcript 11/10/2021
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10 LONDON, Nov. 2, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter 2021 financial results on Wednesday, November 10, 2021. On the day of the release, LumiraDx will host a conference call and webcast at 8 AM Eastern Time to review the financial results and business highlights. 11/02/2021
Why Are LumiraDx Shares Trading Higher Today? LumiraDx (NASDAQ:LMDX) has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application. 10/20/2021
Here is how LumiraDx is making COVID-19 testing easier LumiraDx (NASDAQ: LMDX) has received emergency user approval for the SARS-CoV-2 Antigen test in India from the Central Drugs Standard Organisation. The diagnostic Antigen test is designed to detect antigen nucleocapsid protein from nasal swab, and results are available within 12 minutes of the sample application. 10/20/2021
LMDX Stock: Why It Substantially Increased Today The stock price of LumiraDx (NASDAQ: LMDX) increased by over 30% pre-market today. This is why it happened. 10/20/2021

Unlock

LMDX Ratings Summary

LMDX Quant Ranking